0001209191-17-067087.txt : 20171222 0001209191-17-067087.hdr.sgml : 20171222 20171222165929 ACCESSION NUMBER: 0001209191-17-067087 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20171221 FILED AS OF DATE: 20171222 DATE AS OF CHANGE: 20171222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Harr Steve CENTRAL INDEX KEY: 0001627387 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36781 FILM NUMBER: 171273192 MAIL ADDRESS: STREET 1: 307 WESTLAKE AVE. NORTH, STE. 300 CITY: SEATTLE STATE: WA ZIP: 98109 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Juno Therapeutics, Inc. CENTRAL INDEX KEY: 0001594864 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 463656275 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 2065821600 MAIL ADDRESS: STREET 1: 400 DEXTER AVENUE NORTH, SUITE 1200 CITY: SEATTLE STATE: WA ZIP: 98109 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-12-21 0 0001594864 Juno Therapeutics, Inc. JUNO 0001627387 Harr Steve C/O 400 DEXTER AVENUE NORTH SUITE 1200 SEATTLE WA 98109 0 1 0 0 CFO & Head, Corp. Development Common Stock 2017-12-21 4 M 0 8750 8.72 A 772082 D Common Stock 2017-12-21 4 S 0 8250 44.7373 D 763832 D Common Stock 2017-12-21 4 S 0 500 45.182 D 763332 D Stock Option (Right to Buy) 8.72 2017-12-21 4 M 0 8750 0.00 D 2024-11-13 Common Stock 8750 98750 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 23, 2014, as amended March 24, 2015. This transaction was executed in multiple trades at prices ranging from $44.15 to $45.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $45.15 to $45.21. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 1/48th of the shares subject to the option vested and became exercisable on December 14, 2014 and 1/48th of the shares subject to the option shall vest monthly thereafter. /s/ Zachary D. Hale, attorney-in-fact 2017-12-22